GlassScriptPhysician profile
Autumn A Whitten
NPI 1740877745
$2,216.32
in general payments reported to CMS, 2019-2025
34 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $711 · 2023: $619 · 2024: $356 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.05 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $193.19 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $144.95 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Sk Life Science, INC. | $130.06 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $126.56 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $121.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $114.48 | 2022-2024 | |
| Amgen INC. | $108.77 | 2022-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $87.46 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.50 | 2022-2023 | |
| Mylan Specialty L.P. | $78.14 | 2021-2023 | Yupelri |
| Axsome Therapeutics, INC. | $70.51 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $68.11 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $58.22 | 2022-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $49.68 | 2022-2024 | Verquvo, Steglatro, Belsomra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $47.71 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $43.89 | 2022 | |
| Xeris Pharmaceuticals, INC. | $41.44 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $30.59 | 2022-2023 | |
| Almatica Pharma LLC | $29.26 | 2021 | |
| Baxter Healthcare | $28.48 | 2023 | Hillrom - Life 2000 Ventilation System |
| Orexo US, INC. | $28.14 | 2023 | Zubsolv |
| Nevro Corp. | $25.94 | 2022 | |
| Corcept Therapeutics | $25.49 | 2025 | Korlym |
| Lundbeck LLC | $21.03 | 2024 | Rexulti |
| Hologic Sales and Service, LLC | $21.03 | 2025 | Aptima, Thinprep 2000 Processor |
| Biohaven Pharmaceuticals, INC. | $20.58 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.68 | 2025 | Vpriv |
| Alkermes, INC. | $18.37 | 2025 | Lybalvi |
| Indivior INC. | $16.24 | 2023 | Sublocade |
| Seqirus USA INC | $14.96 | 2022 | |
| Exact Sciences Corporation | $14.51 | 2025 | The Cologuard Plus Collection Kit |
| Advanced Respiratory, INC | $14.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Whitten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.